UBS AM’s Cymabay Therapeutics CBAY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-85,842
| Closed | -$2.03M | – | 2577 |
|
|
2023
Q4 | $2.03M | Buy |
85,842
+9,716
| +13% | +$173K | ﹤0.01% | 1681 |
|
|
2023
Q3 | $1.14M | Buy |
76,126
+7,091
| +10% | +$94K | ﹤0.01% | 1888 |
|
|
2023
Q2 | $602K | Hold |
69,035
| – | – | ﹤0.01% | 2245 |
|
|
2023
Q1 | $602K | Buy |
+69,035
| New | +$553K | ﹤0.01% | 2245 |
|
|
2021
Q2 | – | Sell |
-109,621
| Closed | -$498K | – | 2786 |
|
|
2021
Q1 | $498K | Buy |
109,621
+24,191
| +28% | +$130K | ﹤0.01% | 2391 |
|
|
2020
Q4 | $490K | Buy |
+85,430
| New | +$647K | ﹤0.01% | 2305 |
|
|
2020
Q2 | – | Sell |
-109,476
| Closed | -$162K | – | 2542 |
|
|
2020
Q1 | $162K | Buy |
109,476
+44,525
| +69% | +$74.8K | ﹤0.01% | 2334 |
|
|
2019
Q4 | $127K | Sell |
64,951
-5,673
| -8% | -$21.3K | ﹤0.01% | 2504 |
|
|
2019
Q3 | $362K | Buy |
70,624
+4,096
| +6% | +$24.8K | ﹤0.01% | 2395 |
|
|
2019
Q2 | $476K | Sell |
66,528
-504,181
| -88% | -$5.71M | ﹤0.01% | 2232 |
|
|
2019
Q1 | $7.58M | Buy |
570,709
+35,223
| +7% | +$375K | 0.01% | 1014 |
|
|
2018
Q4 | $4.21M | Sell |
535,486
-50,749
| -9% | -$483K | ﹤0.01% | 1147 |
|
|
2018
Q3 | $6.5M | Buy |
586,235
+17,949
| +3% | +$223K | ﹤0.01% | 1054 |
|
|
2018
Q2 | $7.63M | Sell |
568,286
-24,930
| -4% | -$312K | 0.01% | 1011 |
|
|
2018
Q1 | $7.71M | Buy |
593,216
+3,726
| +0.6% | +$46.3K | 0.01% | 1007 |
|
|
2017
Q4 | $5.42M | Buy |
+589,490
| New | +$5.04M | ﹤0.01% | 1085 |
|
Other funds holding CBAY
UBS AM's CBAY Position: Q1 2024 in Review
UBS AM sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 85,842 shares — an estimated $2.03M sold.
UBS AM first reported a position in CBAY in Q4 2017 and held it in 16 quarters. The position peaked at $7.71M in Q1 2018. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.
- UBS AM reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
- UBS AM sold 85,842 Cymabay Therapeutics shares in Q1 2024, an estimated $2.03M.
- UBS AM first reported a position in Cymabay Therapeutics in Q4 2017 and held it in 16 quarters.
- UBS AM's Cymabay Therapeutics position peaked at $7.71M in Q1 2018.
- 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.
Based on UBS AM's 13F filing for Q1 2024, filed 15 May 2024.